Αρχική World News Abemaciclib Improves PFS at Six Months Among Patients with High-Grade Meningiomas Harbouring... World News Abemaciclib Improves PFS at Six Months Among Patients with High-Grade Meningiomas Harbouring NF2 or CDK Pathway Alterations Από Ogkologos - 26 Ιανουαρίου, 2026 560 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Alliance A071401 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Home Is Where the Heart Is 8 Νοεμβρίου, 2019 Lo que debe saber sobre el cáncer de pulmón 16 Οκτωβρίου, 2020 ESMO Immuno-Oncology Congress 2022, 7-9 December, Geneva, Switzerland 29 Νοεμβρίου, 2022 Cancer Prevention and Screening Account for Most Cancer Deaths Averted Among... 3 Φεβρουαρίου, 2025 Φόρτωση περισσοτέρων HOT NEWS Toripalimab Becomes First Immunotherapy Drug Approved for Nasopharyngeal Cancer Manipulating an Immune Cell May Make Radiation Therapy More Effective, Study... 17 Old Fashioned Ways to Get Rid of Ants in Your... Study Confirms Dinutuximab Extends Life for Children with High-Risk Neuroblastoma